Clinical trials: Adenocarcinoma of the Pancreas
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00085371
- Testing
- triapine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Pancreatic Cancer
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with…
- Trial name
- NCT03190265
- Testing
- Cyclophosphamide, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack…
- Trial name
- EMPIRE (NCT06843551)
- Testing
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Spieler
Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases, Pancreatic Elastase 1, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06041009
- Testing
- Pancreatic elastase-1 in blood serum
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Pancreatic Cancer
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma.
- Trial name
- NCT01360593
- Testing
- Gemcitabine, Capecitabine, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- David A. Clump, MD, PhD
Pancreatic Adenocarcinoma, Interventional Imaging
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma
The aim of the study is to evaluate the use of irreversible electroporation in the treatment of locally advanced cancers of the head of pancreas with vascular spread.
- Trial name
- NCT03105921
- Testing
- NanoKnife
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Poitiers University Hospital
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Pancreatic Adenocarcinoma
Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration.
- Trial name
- NCT02514421
- Testing
- Electroporation, gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pancreas Cancer
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.
- Trial name
- NCT03760614
- Testing
- Entinostat, FOLFOX regimen
- Sponsor
- Abramson Cancer Center at Penn Medicine
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT04216758
- Testing
- nab-paclitaxel, Gemcitabine, tegafur
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Pancreatic Adenocarcinoma
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT02436668
- Testing
- Ibrutinib, Gemcitabine, Nab-paclitaxel
- Where
- 86 sites in United States, Belgium and 6 more
- Volunteers
- 430 people
- Sponsor
- Pharmacyclics LLC.
Pancreatic Ductal Adenocarcinoma (PDAC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal…
- Trial name
- FAPI-PRO (NCT07217717)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced…
- Trial name
- NCT06261359
- Testing
- CEND-1, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Ductal Adenocarcinoma (PDAC)
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture…
- Trial name
- PANC-CTC (NCT03032913)
- Testing
- Blood samples, Portal vein blood sample
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Bordeaux
Pancreatic Adenocarcinoma, Chronic Pancreatitis
Endoscopic Ultrasound Elastography in Pancreatic Masses
The aim of the study is to assess elastography during EUS examinations of focal pancreatic masses, and to consequently differentiate benign versus malignant pancreatic masses in a prospective multi-center design.
- Trial name
- EUS-EG (NCT00909103)
- Where
- 18 sites in Belgium, Denmark and 8 more
- Volunteers
- 285 people
- Sponsor
- University of Medicine and Pharmacy Craiova
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.